<p>加利福尼亞州紅木城 --（商業資訊）--Adicet Bio, Inc.（納斯達克代碼：ACET）是一家臨牀階段的生物技術公司，專注於發現和開發用於自身免疫疾病和癌症的異體伽馬δ T 細胞療法，今天宣佈其董事會決定實施 Adicet 普通股的 1 比 16 反向股票拆分，面值為每股 0.0001 美元。</p>
<p>董事會批准的反向股票拆分比例在 2025 年 12 月 19 日舉行的 Adicet 2025 年特別股東大會上由公司股東授權的反向股票拆分比例的先前披露範圍內。反向股票拆分將於 2025 年 12 月 30 日東部時間凌晨 12:01 生效，Adicet 的普通股將於 2025 年 12 月 30 日開盤時在納斯達克資本市場以拆分調整後的基礎開始交易。反向股票拆分生效時，Adicet 的普通股將被分配 CUSIP 號碼 007002207。</p>
<p>當反向股票拆分生效時，Adicet 已發行的每十六（16）股普通股將合併為一股已發行的普通股，面值不變。這將使已發行的普通股數量從大約 1.533 億股減少到大約 960 萬股。反向股票拆分不會影響 Adicet 授權的普通股的絕對數量，仍將保持在 3 億股，但 Adicet 未來可發行的普通股總數將增加。</p>
<p>還將對 Adicet 的股權激勵計劃下授予和可發行的普通股數量進行比例調整，以及 Adicet 的未到期股票期權和其他股權證券的行使價格和可發行股份數量。所有未到期的預先融資認股權證也將根據其條款進行調整，這將導致對可通過行使這些認股權證發行的股份數量和這些認股權證的行使價格進行比例調整。</p>
<p>在反向股票拆分中不會發行任何零碎股份。原本有權獲得零碎股份的股東將自動有權獲得現金以代替這些零碎股份。</p>
<p>以賬面形式持有股份或通過銀行、經紀人或其他代理人持有股份的股東無需採取任何行動，反向股票拆分的結果將在 2025 年 12 月 30 日或之後反映在他們的賬户中。這些受益持有人可以聯繫他們的銀行、經紀人或代理人以獲取更多信息。</p>
<p>反向股票拆分旨在使 Adicet 重新符合納斯達克資本市場持續上市的最低出價要求。</p>
<p><strong>關於 Adicet Bio, Inc.</strong></p>
<p>Adicet Bio, Inc.是一家臨牀階段的生物技術公司，專注於發現和開發用於自身免疫疾病和癌症的異體伽馬δ T 細胞療法。Adicet 正在推進一系列 “現成” 的伽馬δ T 細胞，這些細胞經過嵌合抗原受體（CARs）工程改造，以促進患者的持久活性。有關更多信息，請訪問我們的網站 https://www.adicetbio.com。</p>
<p><strong>前瞻性聲明</strong></p>
<p>本新聞稿包含 Adicet 根據 1995 年《私人證券訴訟改革法》所定義的 “前瞻性聲明”，涉及 Adicet 的業務和運營。詞語 “預期”、“相信”、“繼續”、“可能”、“估計”、“期望”、“打算”、“可能”、“計劃”、“潛在”、“預測”、“項目”、“應該”、“目標”、“將” 和類似表達旨在識別前瞻性聲明，儘管並非所有前瞻性聲明都包含這些識別詞。這些前瞻性聲明包括但不限於關於反向股票拆分的時間和完成情況、反向股票拆分的預期效果以及 Adicet 普通股在拆分調整後基礎上的交易情況，以及反向股票拆分對 Adicet 重新符合納斯達克上市標準的能力的影響。</p>
<p>本新聞稿中的任何前瞻性聲明均基於管理層對未來事件的當前預期和信念，並受到多種風險和不確定性的影響，這些風險和不確定性可能導致實際結果與這些前瞻性聲明中所列或暗示的結果存在重大和不利的差異，包括但不限於全球經濟狀況和公共衞生緊急情況對 Adicet 業務和財務結果的影響，包括對我們臨牀前和臨牀研究、業務運營、員工招聘和留任以及籌集額外資本能力的干擾；Adicet 執行其戰略的能力，包括在預期時間內獲得必要的監管批准（如果有的話）；臨牀前或臨牀研究的積極結果（包括中期結果）不一定能預測未來或正在進行的研究的結果；臨牀研究可能未能證明 Adicet 產品候選者的安全性和有效性，這將阻止、延遲或限制監管批准和商業化的範圍；美國食品和藥物管理局及其他外國監管機構的監管批准過程漫長、耗時且本質上不可預測；以及 Adicet 滿足生產和產品發佈預期的能力。有關這些及其他風險和不確定性的討論，以及可能導致 Adicet 實際結果與前瞻性聲明中所包含的結果不同的其他重要因素，請參見 Adicet 最近的 10-K 表格年度報告、10-Q 表格季度報告及其後續向美國證券交易委員會（SEC）提交的文件中標題為 “風險因素” 的部分，以及 Adicet 在 SEC 的其他文件中對潛在風險、不確定性和其他重要因素的討論。本新聞稿中的所有信息均截至發佈之日，Adicet 不承擔更新該信息的義務，除非法律要求。</p>
<p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTEyMjY2NjE3OTNyMQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTEyMjY2NjE3OTNyMQ"/></p>
<p>在 businesswire.com 查看源版本：https://www.businesswire.com/news/home/20251226661793/en/</p>
<p><strong>Adicet Bio, Inc.</strong></p>
<p><strong>投資者和媒體聯繫人</strong></p>
<p>Anne Bowdidge</p>
<p>abowdidge@adicetbio.com</p>
<p><strong>Penelope Belnap</strong></p>
<p><strong>Precision AQ</strong></p>
<p>212-362-1200</p>
<p>Penelope.belnap@precisionaq.com</p>
<p>來源：Adicet Bio, Inc.</p>

ACET

<p>Adicet Bio, Inc. 宣佈將於 2025 年 12 月 30 日實施 1 股換 16 股的反向股票拆分。此舉旨在重新符合納斯達克的最低報價要求。反向拆分將使流通股從約 1.533 億股減少至 960 萬股，而不會影響總授權股份。股權激勵計劃和股票期權將進行相應的調整。不會發行零碎股份；將提供現金作為替代。調整後的交易將在生效日期當天在納斯達克開始</p>

<p>REDWOOD CITY, Calif.--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that its board of directors has determined to effect a one-for-16 reverse stock split of Adicet’s common stock, par value $0.0001 per share.</p>
<div class="lb-trans"><p>加利福尼亞州紅木城 --（商業資訊）--Adicet Bio, Inc.（納斯達克代碼：ACET）是一家臨牀階段的生物技術公司，專注於發現和開發用於自身免疫疾病和癌症的異體伽馬δ T 細胞療法，今天宣佈其董事會決定實施 Adicet 普通股的 1 比 16 反向股票拆分，面值為每股 0.0001 美元。</p>
</div><p>The reverse stock split ratio approved by the board of directors is within the previously disclosed range of ratios for a reverse stock split authorized by the stockholders of the company at the 2025 Special Meeting of Stockholders of Adicet held on December 19, 2025. The reverse stock split will take effect at 12:01 a.m. Eastern Time on December 30, 2025, and Adicet’s common stock will begin trading on a split-adjusted basis on The Nasdaq Capital Market as of the opening of trading on December 30, 2025. The CUSIP number of 007002207 will be assigned to Adicet’s common stock when the reverse stock split becomes effective.</p>
<div class="lb-trans"><p>董事會批准的反向股票拆分比例在 2025 年 12 月 19 日舉行的 Adicet 2025 年特別股東大會上由公司股東授權的反向股票拆分比例的先前披露範圍內。反向股票拆分將於 2025 年 12 月 30 日東部時間凌晨 12:01 生效，Adicet 的普通股將於 2025 年 12 月 30 日開盤時在納斯達克資本市場以拆分調整後的基礎開始交易。反向股票拆分生效時，Adicet 的普通股將被分配 CUSIP 號碼 007002207。</p>
</div><p>When the reverse stock split becomes effective, every sixteen (16) of Adicet’s issued shares of common stock will be combined into one issued share of common stock, without any change to the par value per share. This will reduce the number of outstanding shares of common stock from approximately 153.3 million shares to approximately 9.6 million shares. The reverse stock split will not affect the absolute number of Adicet’s authorized shares of common stock, which will remain at 300,000,000, but the total number of shares of Adicet’s common stock available for future issuance will increase.</p>
<div class="lb-trans"><p>當反向股票拆分生效時，Adicet 已發行的每十六（16）股普通股將合併為一股已發行的普通股，面值不變。這將使已發行的普通股數量從大約 1.533 億股減少到大約 960 萬股。反向股票拆分不會影響 Adicet 授權的普通股的絕對數量，仍將保持在 3 億股，但 Adicet 未來可發行的普通股總數將增加。</p>
</div><p>Proportional adjustments will also be made to the number of shares of common stock awarded and available for issuance under Adicet’s equity incentive plans, as well as the exercise price and the number of shares issuable upon the exercise or conversion of Adicet’s outstanding stock options and other equity securities under Adicet’s equity incentive plans. All outstanding pre-funded warrants will also be adjusted in accordance with their terms, which will result in proportionate adjustments being made to the number of shares issuable upon exercise of such warrants and to the exercise prices of such warrants, as applicable.</p>
<div class="lb-trans"><p>還將對 Adicet 的股權激勵計劃下授予和可發行的普通股數量進行比例調整，以及 Adicet 的未到期股票期權和其他股權證券的行使價格和可發行股份數量。所有未到期的預先融資認股權證也將根據其條款進行調整，這將導致對可通過行使這些認股權證發行的股份數量和這些認股權證的行使價格進行比例調整。</p>
</div><p>No fractional shares will be issued in connection with the reverse stock split. Stockholders who would otherwise be entitled to receive fractional shares will automatically be entitled to receive cash in lieu of such fractional share.</p>
<div class="lb-trans"><p>在反向股票拆分中不會發行任何零碎股份。原本有權獲得零碎股份的股東將自動有權獲得現金以代替這些零碎股份。</p>
</div><p>Stockholders with shares held in book-entry form or through a bank, broker, or other nominee are not required to take any action and will see the consequence of the reverse stock split reflected in their accounts on or after December 30, 2025. Such beneficial holders may contact their bank, broker, or nominee for more information.</p>
<div class="lb-trans"><p>以賬面形式持有股份或通過銀行、經紀人或其他代理人持有股份的股東無需採取任何行動，反向股票拆分的結果將在 2025 年 12 月 30 日或之後反映在他們的賬户中。這些受益持有人可以聯繫他們的銀行、經紀人或代理人以獲取更多信息。</p>
</div><p>The reverse stock split is intended to enable Adicet to regain compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market.</p>
<div class="lb-trans"><p>反向股票拆分旨在使 Adicet 重新符合納斯達克資本市場持續上市的最低出價要求。</p>
</div><p><strong>About Adicet Bio, Inc.</strong></p>
<div class="lb-trans"><p><strong>關於 Adicet Bio, Inc.</strong></p>
</div><p>Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. For more information, please visit our website at https://www.adicetbio.com.</p>
<div class="lb-trans"><p>Adicet Bio, Inc.是一家臨牀階段的生物技術公司，專注於發現和開發用於自身免疫疾病和癌症的異體伽馬δ T 細胞療法。Adicet 正在推進一系列 “現成” 的伽馬δ T 細胞，這些細胞經過嵌合抗原受體（CARs）工程改造，以促進患者的持久活性。有關更多信息，請訪問我們的網站 https://www.adicetbio.com。</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性聲明</strong></p>
</div><p>This press release contains “forward-looking statements” of Adicet within the meaning of the Private Securities Litigation Reform Act of 1995 relating to the business and operations of Adicet. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, but are not limited to, express or implied statements regarding: the timing and completion of the reverse stock split, the intended effects of the reverse stock split and trading of Adicet’s common stock on a split-adjusted basis, and the effect the reverse stock split will have on Adicet’s ability to regain compliance with the Nasdaq listing standards.</p>
<div class="lb-trans"><p>本新聞稿包含 Adicet 根據 1995 年《私人證券訴訟改革法》所定義的 “前瞻性聲明”，涉及 Adicet 的業務和運營。詞語 “預期”、“相信”、“繼續”、“可能”、“估計”、“期望”、“打算”、“可能”、“計劃”、“潛在”、“預測”、“項目”、“應該”、“目標”、“將” 和類似表達旨在識別前瞻性聲明，儘管並非所有前瞻性聲明都包含這些識別詞。這些前瞻性聲明包括但不限於關於反向股票拆分的時間和完成情況、反向股票拆分的預期效果以及 Adicet 普通股在拆分調整後基礎上的交易情況，以及反向股票拆分對 Adicet 重新符合納斯達克上市標準的能力的影響。</p>
</div><p>Any forward-looking statements in this press release are based on management’s current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements, including without limitation, the effect of global economic conditions and public health emergencies on Adicet’s business and financial results, including with respect to disruptions to our preclinical and clinical studies, business operations, employee hiring and retention, and ability to raise additional capital; Adicet’s ability to execute on its strategy including obtaining the requisite regulatory approvals on the expected timeline, if at all; that positive results, including interim results, from a preclinical or clinical study may not necessarily be predictive of the results of future or ongoing studies; clinical studies may fail to demonstrate adequate safety and efficacy of Adicet’s product candidates, which would prevent, delay, or limit the scope of regulatory approval and commercialization; and regulatory approval processes of the U.S. Food and Drug Administration and comparable foreign regulatory authorities are lengthy, time-consuming, and inherently unpredictable; and Adicet’s ability to meet production and product release expectations. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause Adicet’s actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in Adicet’s most recent annual report on Form 10-K, quarterly reports on Form 10-Q and subsequent filings with the U.S. Securities and Exchange Commission (SEC), as well as discussions of potential risks, uncertainties, and other important factors in Adicet’s other filings with the SEC. All information in this press release is as of the date of the release, and Adicet undertakes no duty to update this information unless required by law.</p>
<div class="lb-trans"><p>本新聞稿中的任何前瞻性聲明均基於管理層對未來事件的當前預期和信念，並受到多種風險和不確定性的影響，這些風險和不確定性可能導致實際結果與這些前瞻性聲明中所列或暗示的結果存在重大和不利的差異，包括但不限於全球經濟狀況和公共衞生緊急情況對 Adicet 業務和財務結果的影響，包括對我們臨牀前和臨牀研究、業務運營、員工招聘和留任以及籌集額外資本能力的干擾；Adicet 執行其戰略的能力，包括在預期時間內獲得必要的監管批准（如果有的話）；臨牀前或臨牀研究的積極結果（包括中期結果）不一定能預測未來或正在進行的研究的結果；臨牀研究可能未能證明 Adicet 產品候選者的安全性和有效性，這將阻止、延遲或限制監管批准和商業化的範圍；美國食品和藥物管理局及其他外國監管機構的監管批准過程漫長、耗時且本質上不可預測；以及 Adicet 滿足生產和產品發佈預期的能力。有關這些及其他風險和不確定性的討論，以及可能導致 Adicet 實際結果與前瞻性聲明中所包含的結果不同的其他重要因素，請參見 Adicet 最近的 10-K 表格年度報告、10-Q 表格季度報告及其後續向美國證券交易委員會（SEC）提交的文件中標題為 “風險因素” 的部分，以及 Adicet 在 SEC 的其他文件中對潛在風險、不確定性和其他重要因素的討論。本新聞稿中的所有信息均截至發佈之日，Adicet 不承擔更新該信息的義務，除非法律要求。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTEyMjY2NjE3OTNyMQ" alt="" original-src="https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20251226661793r1&amp;sid=acqr8&amp;distro=nx&amp;lang=en"/></p>
<p>View source version on businesswire.com: https://www.businesswire.com/news/home/20251226661793/en/</p>
<div class="lb-trans"><p>在 businesswire.com 查看源版本：https://www.businesswire.com/news/home/20251226661793/en/</p>
</div><p><strong>Adicet Bio, Inc.</strong></p>
<div class="lb-trans"><p><strong>Adicet Bio, Inc.</strong></p>
</div><p><strong>Investor and Media Contacts</strong></p>
<div class="lb-trans"><p><strong>投資者和媒體聯繫人</strong></p>
</div><p>Anne Bowdidge</p>
<div class="lb-trans"><p>Anne Bowdidge</p>
</div><p>abowdidge@adicetbio.com</p>
<div class="lb-trans"><p>abowdidge@adicetbio.com</p>
</div><p><strong>Penelope Belnap</strong></p>
<div class="lb-trans"><p><strong>Penelope Belnap</strong></p>
</div><p><strong>Precision AQ</strong></p>
<div class="lb-trans"><p><strong>Precision AQ</strong></p>
</div><p>212-362-1200</p>
<div class="lb-trans"><p>212-362-1200</p>
</div><p>Penelope.belnap@precisionaq.com</p>
<div class="lb-trans"><p>Penelope.belnap@precisionaq.com</p>
</div><p>Source: Adicet Bio, Inc.</p>
<div class="lb-trans"><p>來源：Adicet Bio, Inc.</p>
</div>

Adicet Bio 宣佈進行反向股票拆分 | ACET 股票新聞